Efficacy of tilmicosin phosphate (Pulmotil premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs.
A double-blind randomized clinical trial was carried out to investigate the efficacy of tilmicosin (Pulmotil premix) for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. The effects of tilmicosin administration in the feed at 400 mg/kg and an injection therapy of clinically diseased pigs with long-acting oxytetracycline (Terramycine LA) at 20 mg/kg bodyweight were compared. Both groups, totalling 147 pigs, were compared during a medication period of 15 days and a post-medication period of 11 days by means of different clinical and performance parameters. During the medication period, the tilmicosin group showed a significant advantage with respect to the number of new disease cases (P < 0.01), and a non-significant advantage regarding the number of removed pigs (P = 0.16), the number of sick pigs that recovered (P = 0.27) and the time to recovery (P = 0.42). During the post-medication period, the pigs of the tilmicosin group showed numerical non-significant benefits (P > 0.05) with respect to the clinical parameters. During the overall study period (26 days), the average daily gain and the feed conversion ratio were both significantly (P < 0.01) better in pigs from the tilmicosin group compared with pigs from the oxytetracycline group. This study demonstrated that in-feed medication of tilmicosin at a dosage of 400 mg/kg is efficacious for the treatment of a clinical respiratory disease outbreak of A. pleuropneumoniae infection in growing-finishing pigs. Compared with oxytetracycline injection of clinically diseased pigs, the tilmicosin treatment is particularly beneficial in the prevention of new disease cases while increasing or maintaining the performance of the pigs.
Hoflack
G
G
Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Maes
D
D
Mateusen
B
B
Verdonck
M
M
de Kruif
A
A
D000189:Actinobacillus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D016977:Actinobacillus pleuropneumoniae / Q000187:drug effects* / Q000254:growth & development; D000821:Animal Feed; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001530:Belgium / Q000453:epidemiology; D004196:Disease Outbreaks / Q000662:veterinary*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D018942:Macrolides; D008297:Male; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D013997:Time Factors; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D018942:Macrolides; C052319:tilmicosin; D015645:Tylosin